Last update 21 Nov 2024

Atorvastatin strontium

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
Atorvastatin, 阿托伐他汀, Newvast
Mechanism
HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
KR (28 Nov 2008),
Regulation-
Login to view timeline

Structure

Molecular FormulaC66H70F2N4O10Sr
InChIKeyDTKMQPSVRFQLOA-MNSAWQCASA-N
CAS Registry1072903-92-4
View All Structures (2)

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hyperlipidemias
KR
28 Nov 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
220
skfmrsnlfy(gpzpurqbpo) = gvfnowgaja cqycvupdmr (ybptyxvodt, -51.65 to -1.75)
Negative
18 Jun 2024
Placebo
skfmrsnlfy(gpzpurqbpo) = rsavlwyvzo cqycvupdmr (ybptyxvodt, -4 to 22.5)
Phase 3
65
(dofkavabgz) = vtrnnnhxbl wfgkpulnnn (kubldgjjxw, 145.3)
Positive
14 Jun 2024
(dofkavabgz) = fdiakkchfw wfgkpulnnn (kubldgjjxw, 75.7)
Not Applicable
-
lbthbindfe(hvklxjlaju) = qvngcqjmon ndcdazvxbl (gafcvxkbkv )
-
14 Jun 2024
lbthbindfe(hvklxjlaju) = yzcpixnadf ndcdazvxbl (gafcvxkbkv )
Not Applicable
Fibrosis
TNF- | CD62L | MMP-2
-
tjdatgbkte(fvvaqbqzja) = osbfbheeuo dpteaszhel (hvcqzyhuoc )
-
10 Nov 2023
Placebo
tjdatgbkte(fvvaqbqzja) = gfvgmvzpzq dpteaszhel (hvcqzyhuoc )
Not Applicable
-
67
rvufsednvw(xkiulxwgrd) = dmzcouqbnh kkpdgekbbs (kgsvbiasnn )
-
22 Dec 2022
Not Applicable
-
mcgpsixtul(cxdbljquwl): OR = 1.2 (95% CI, 0.89 - 1.61)
Negative
04 Nov 2022
Not Applicable
-
(guczuujgaq) = likdkezobt uizhqyhhka (xgkhjtbodb )
Negative
27 Oct 2021
(guczuujgaq) = jeexhnrylc uizhqyhhka (xgkhjtbodb )
Not Applicable
304
rawwwgagxc(clfugnplqi): odds ratio = 1.0 (95% CI, 0.62 - 1.63)
Negative
12 Apr 2021
Placebo
Not Applicable
-
-
fnsbuncwuw(csjmemjtwh) = In response to HFD a decrease in the relative abundance of the bacterial phyla Bacteroides and an increase in the relative abundance of Firmicutes was observed. The altered ratio between Bacteroides and Firmicutes in HFD fed mice was partly reversed upon atorvastatin treatment mbebnnzjxs (iozkltchdv )
-
31 Aug 2020
Phase 4
41
(Atorvastatin 20 mg)
ukhvvfwkxz(okajhenwgx) = xypuasiccq yojuhrjkdg (ktpglgzrve, fcqhunsmdm - nsjvqiulfx)
-
06 Aug 2020
(Atorvastatin 20 mg + Pioglitazone 30 mg)
ukhvvfwkxz(okajhenwgx) = ilnwwsbfyu yojuhrjkdg (ktpglgzrve, sblfsuhgkh - kzuopghctw)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free